KBP-2205

Primary purpose: Evaluate the safety and tolerability of multiple doses of KBP-2205 in subjects with advanced malignant solid tumors Determine the maximum tolerated dose (MTD) or the highest dose (MAD) Provide a basis for the Phase II recommended dose (RP2D) Secondary purpose: Characterize the pharmacokinetic (PK) characteristics of multiple doses of KBP-2205 in subjects with advanced malignant solid tumors Observe the preliminary anti-tumor activity of KBP-2205 in the treatment of advanced solid tumors Study the effect of KBP-2205 on the ECG QTc interval to provide a basis for the subsequent evaluation of potential cardiac toxicity Exploratory purpose: Study the relationship between the expression level of biomarkers and the anti-tumor activity of KBP-2205 to provide a basis for the selection of biomarkers in subsequent clinical trials Study the relationship between KBP-2205 exposure and selected study endpoints (such as safety and efficacy)